FDA Clears Oricula Therapeutics Investigational New Drug Application for Clinical Trials
ORC-13661 Could be the First Medicine Approved Specifically to Prevent Hearing Loss of Patients Using Certain Antibiotics
SEATTLE, Feb. 5, 2018 -- (Healthcare Sales & Marketing Network) -- ORICULA THERAPEUTICS, LLC., a biotech company introducing medic... Biopharmaceuticals, FDA Oricula Therapeutics, ORC-13661, hearing loss
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Clinical Trials | Investigational New Drugs | Marketing | New Drug Applications | Pharmaceuticals